Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Helen Kakkassery; Esme Carpenter; Piers E.M. Patten; Sheeba Irshad

doi:10.1016/j.molmed.2022.07.006

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Helen Kakkassery, Esme Carpenter, Piers E.M. Patten, Sheeba Irshad^*

^*Corresponding author for this work

Comprehensive Cancer Centre

Research output: Contribution to journal › Review article › peer-review

15 Citations (Scopus)

Abstract

Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research.

Original language	English
Pages (from-to)	1082-1099
Number of pages	18
Journal	TRENDS IN MOLECULAR MEDICINE
Volume	28
Issue number	12
DOIs	https://doi.org/10.1016/j.molmed.2022.07.006
Publication status	Published - Dec 2022

Keywords

cancer
COVID-19
haematological cancers
SARS-CoV-2
seroconversion
vaccine immunogenicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.molmed.2022.07.006

Cite this

@article{5cf99fdea28c4e319d299e133324a7d6,

title = "Immunogenicity of SARS-CoV-2 vaccines in patients with cancer",

abstract = "Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research.",

keywords = "cancer, COVID-19, haematological cancers, SARS-CoV-2, seroconversion, vaccine immunogenicity",

author = "Helen Kakkassery and Esme Carpenter and Patten, {Piers E.M.} and Sheeba Irshad",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = dec,

doi = "10.1016/j.molmed.2022.07.006",

language = "English",

volume = "28",

pages = "1082--1099",

journal = "TRENDS IN MOLECULAR MEDICINE",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

AU - Kakkassery, Helen

AU - Carpenter, Esme

AU - Patten, Piers E.M.

AU - Irshad, Sheeba

PY - 2022/12

Y1 - 2022/12

N2 - Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research.

AB - Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been shown to impose a higher burden on cancer patients than on the general population. Approved vaccines for use include new technology mRNA vaccines such as BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna), and nonreplicating viral vector vaccines such as Ad26.COV2.S (Johnson & Johnson) and AZD1222 (AstraZeneca). Impaired or delayed humoral and diminished T-cell responses are evident in patients with cancer, especially in patients with haematological cancers or those under active chemotherapy. Herein we review the current data on vaccine immunogenicity in cancer patients, including recommendations for current practice and future research.

KW - cancer

KW - COVID-19

KW - haematological cancers

KW - SARS-CoV-2

KW - seroconversion

KW - vaccine immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=85136262171&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2022.07.006

DO - 10.1016/j.molmed.2022.07.006

M3 - Review article

AN - SCOPUS:85136262171

SN - 1471-4914

VL - 28

SP - 1082

EP - 1099

JO - TRENDS IN MOLECULAR MEDICINE

JF - TRENDS IN MOLECULAR MEDICINE

IS - 12

ER -

Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this